Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan

Clinical Respiratory Journal

Volumn 9, Issue 2, 2015, Pages 228-232

  Yoshino, Yusuke ^a   Seo, Kazunori ^a   Koga, Ichiro ^a   Kitazawa, Takatoshi ^a   Ota, Yasuo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical efficacy; Influenza; Oseltamivir; Peramivir

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONSCIOUSNESS; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLASGOW COMA SCALE; HUMAN; INCIDENCE; JAPAN; MALE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WINTER; AGED; COMPARATIVE STUDY; HOSPITALIZATION; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; RETROSPECTIVE STUDY; SEASON; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYCLOPENTANES; FEMALE; GUANIDINES; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; OSELTAMIVIR; RETROSPECTIVE STUDIES; SEASONS; TREATMENT OUTCOME;

EID: 84926333053     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12129     Document Type: Article

References (10)

1. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12: 15-22.
2. Taubenberger JK, Morens DM. Pandemic influenza - including a risk assessment of H5N1. Rev Sci Tech. 2009;28: 187-202.
3. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361: 2204-2207.
4. Kohno S, Yen MY, Cheong HJ, etal. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55: 5267-5276.
5. Shobugawa Y, Saito R, Sato I, etal. Clinical effectiveness of neuraminidase inhibitors - oseltamivir, zanamivir, laninamivir, and peramivir - for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother. 2012;18: 858-864.
6. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012; doi: 10.1155/2012/834181.
7. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother. 2010;44: 1240-1249.
8. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS ONE. 2012;7: e40261.
9. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207: 553-563.
10. Aoki FY, Macleod MD, Paggiaro P, etal. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51: 123-129.